Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2012 Mar;15(1):93-9.
doi: 10.1038/pcan.2011.50. Epub 2011 Oct 25.

Efficacy and safety of leuprolide acetate 6-month depot for suppression of testosterone in patients with prostate cancer

A Spitz  1 , J M Young, L Larsen, C Mattia-Goldberg, J Donnelly, K Chwalisz
Affiliations
Free PMC article
Clinical Trial

Efficacy and safety of leuprolide acetate 6-month depot for suppression of testosterone in patients with prostate cancer

A Spitz et al. Prostate Cancer Prostatic Dis. 2012 Mar.
Free PMC article

Abstract

Background: This open-label study evaluated the efficacy and safety of a new leuprolide acetate 45 mg 6-month depot formulation in 151 men with prostate cancer who received 2 intramuscular injections administered 24 weeks apart.

Methods: The primary efficacy measurement was the proportion of patients achieving suppression of serum testosterone to ≤ 50 ng dl(-1) from week 4 through week 48. Adverse events (AEs) and hormonal and safety laboratory values were monitored.

Results: The primary efficacy end point was achieved in 93.4% of subjects (95% confidence interval (89.2%, 97.6%)). There were nine escapes from testosterone suppression during the study, none of which were accompanied by a rise in PSA. By week 4, mean testosterone concentration was suppressed below castrate levels to 15.9 ng dl(-1); suppression was maintained for the entire 24-week duration of each depot injection. No mean increase in testosterone was observed after the second injection. Mean PSA levels were maintained below 3 ng ml(-1) from week 14 through the 48-week treatment period. The most frequent AE was flushing (58.3%). Injection site reactions were reported in 24.5% of patients.

Conclusions: Leuprolide acetate 45 mg 6-month depot demonstrated rapid and sustained testosterone suppression through 12 months and was well tolerated. This 6-month leuprolide acetate depot will decrease the number of annual injections in the treatment of prostate cancer.

Trial registration: ClinicalTrials.gov NCT00626431.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Subject disposition. Flow of subjects through the trial. aThree patients had no testosterone value for week 4 and were excluded fron the intent-to-treat (ITT) population for the primary efficacy endpoint, 5 subjects were censored in the adjusted primary endpoint; bsubject accountability determined by investigator.
Figure 2
Figure 2
Mean testosterone levels (a) and mean luteinizing hormone (LH) concentrations (b) during the treatment period. The dashed line in (a) represents castrate levels for serum testosterone (50 ng dl−1). Time points for administration of leuprolide acetate 6-month depot injections are indicated in both panels.
Figure 3
Figure 3
Mean PSA levels during the treatment period. Time points for administration of leuprolide acetate 6-month depot injections are indicated.
See this image and copyright information in PMC

References

    1. American Cancer Society Cancer Facts and Figures 2010Available at http://www.cancer.org/acs/groups/content/@nho/ documents/document/acspc-... . Accessed 12 August 2010.
    1. Cassileth BR, Soloway MS, Vogelzang NJ, Schellhammer PS, Seidmon EJ, Hait HI, et al. Patients' choice of treatment in Stage D prostate cancer. Urology. 1989;33 (5 Suppl:57–62. - PubMed
    1. Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008;102:1531–1538. - PubMed
    1. McLeod DG. Hormonal therapy: historical perspective to future directions. Urology. 2003;61 (2 Suppl 1:3–7. - PubMed
    1. Berges R, Bello U. Effect of a new leuprorelin formulation on testosterone levels in patients with advanced prostate cancer. Curr Med Res Opin. 2006;22:649–655. - PubMed

Publication types

MeSH terms

Associated data